

#### **VEGFR2**

Catalog # PVGS1693

### **Specification**

### **VEGFR2 - Product Information**

Primary Accession **Species** Human P35968-1

Sequence Ala20-Glu764

**Purity** 

> 95% as determined by Bis-Tris PAGE<br/>> > 95% as determined by HPLC

**Endotoxin Level** 

Less than 1 EU per µg by the LAL method.

**Biological Activity** 

Immobilized VEGFR2, Avi & His, Human (Cat.No.: Z03811) at 0.5  $\mu$ g/ml can bind AntiVEGFR2 Antibody.

**Expression System** 

**HEK293** 

Theoretical Molecular Weight

86.2 kDa

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4.

#### Reconstitution

Centrifuge the tube before opening. Reconstituting to a concentration more than 100  $\mu$ g/ml is recommended. Dissolve the lyophilized protein in distilled water.

## Storage & Stability

Upon receiving, the lyophilized product remains stable up to 6 months at -20 °C or below as supplied from date of receipt.-80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

## **VEGFR2 - Additional Information**

# **Target Background**

The kinase insert domain receptor (KDR), also known as vascular endothelial growth factor receptor 2 (VEGFR-2), is a type IV receptor tyrosine kinase that plays a crucial role in various biological processes, including embryonic vasculature development, angiogenesis regulation, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. It acts as a cell-surface receptor for VEGFA, VEGFB, and PGF. The human gene encoding KDR is also known as CD309 and Flk1 (Fetal Liver Kinase 1). VEGFR2 is a key regulator of angiogenesis.



# **VEGFR2 - Protein Information**

## **VEGFR2 - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

**VEGFR2 - Images**